RSC Advances
Paper
Diethyl 3-chlorophenylphosphonate (1h). 31P NMR (CDCl3) d
17.5; 13C NMR (CDCl3) d 16.2 (d, J ¼ 6.4, CH3), 62.3 (d, J ¼ 5.5,
CH2), 129.69 (d, J ¼ 9.2, C5), 129.74 (d, J ¼ 16.3, C6), 130.7 (d, J ¼
187.9, C1), 131.6 (d, J ¼ 10.7, C3), 132.4 (d, J ¼ 3.0, C4), 134.7 (d, J
(CDCl3) d 1.36 (t, 3H, J ¼ 7.1, CH3), 4.01–4.16 (m, 2H, OCH2),
7.39–7.58 (m, 6H, ArH), 7.75–7.88 (m, 4H, ArH); [M + H]+
¼
247.0888, C14H16O2P requires 247.0888.
Propyl diphenylphosphinate (3b). White crystals; mp.: 92–
93 ꢀC, mp.:44 89–91 ꢀC; 31P NMR (CDCl3) d 33.5; 13C NMR
(CDCl3) d 10.3 (CH2CH3), 24.0 (d, J ¼ 6.7, OCH2CH2), 66.4 (d, J ¼
6.1, OCH2), 128.6 (d, J ¼ 13.1, C2)*, 131.7 (d, J ¼ 10.1, C3)*, 131.8
1
¼ 20.3, C2); H NMR (CDCl3) d 1.30 (t, 6H, J ¼ 7.1, CH3), 3.96–
4.20 (m, 4H, OCH2), 7.40–7.31 (m, 1H, ArH), 7.43–7.51 (m, 1H,
ArH), 7.59–7.81 (m, 2H, ArH); [M
10H15O3P35Cl requires 249.0447.
Diethyl 3-uorophenylphosphonate (1j). 31P NMR (CDCl3) d
+
H]+
¼
249.0448,
1
(d, J ¼ 137.2, C1), 132.2 (d, J ¼ 2.8, C4), * may be reversed; H
C
NMR (CDCl3) d 0.94 (t, 3H, J ¼ 7.4, CH3), 1.71–1.80 (m, 2H,
OCH2CH2), 3.99 (q, 2H, J ¼ 6.7, OCH2), 7.39–7.53 (m, 6H, ArH),
7.79–7.88 (m, 4H, ArH); [M + H]+ ¼ 261.1040, C15H18O2P
requires 261.1039.
16.7 (d, J ¼ 8.7); dP (CDCl3)37 17.4; 13C NMR (CDCl3) d 16.3 (d, J1
¼ 6.4, CH3), 62.4 (d, J1 ¼ 5.5, CH2), 118.6 (dd, J1 ¼ 10.5, J2 ¼ 22.3,
C2), 119.5 (dd, J1 ¼ 3.1, J2 ¼ 21.1, C4), 127.5 (dd, J1 ¼ 9.2, J2 ¼ 3.3,
C6), 130.5 (dd, J1 ¼ 17.5, J2 ¼ 7.5, C5), 131.0 (dd, J1 ¼ 188.9, J2 ¼
6.2, C1), 162.4 (dd, J1 ¼ 21.4, J2 ¼ 249.4, C3); 1H NMR (CDCl3) d
1.29 (t, 6H, J ¼ 7.0, CH3), 3.99–4.20 (m, 4H, OCH2), 7.13–7.23 (m,
1H, ArH), 7.33–7.60 (m, 3H, ArH); [M + H]+ ¼ 233.0743,
Isopropyl diphenylphosphinate (3c). White crystals; mp.: 101–
31
102 C, mp.: 98–100 C; P NMR (CDCl3) d 30.0, dP (CDCl3)43
31.4; 13C NMR (CDCl3) d 24.4 (d, J ¼ 4.2, CH3), 70.3 (d, J ¼ 6.0,
OCH), 128.5 (d, J ¼ 13.1, C2)*, 131.7 (d, J ¼ 10.1, C3)*, 132.0 (d, J
ꢀ
43
ꢀ
1
¼ 2.8, C4), 132.4 (d, J ¼ 137.3, C1), * may be reversed; H NMR
C
10H15O3PF requires 233.0743.
Diethyl 3-ethoxycarbonylphenylphosphonate (1l). 31P NMR
(CDCl3) d 1.34 (d, 6H, J ¼ 6.1, CH3), 4.57–4.74 (m, 1H, OCH),
7.36–7.56 (m, 6H, ArH), 7.75–7.90 (m, 4H, ArH); [M + H]+
¼
(CDCl3) d 17.4; 13C NMR (CDCl3) d 14.4 (COCH2CH3), 16.4 (d, J ¼
6.4, POCH2CH3), 61.4 (COCH2), 62.4 (d, J ¼ 5.5, POCH2), 128.7
(d, J ¼ 15.0, C2), 129.3 (d, J ¼ 189.7, C1), 130.9 (d, J ¼ 15.1, C6),
132.8 (d, J ¼ 10.9, C5), 133.3 (d, J ¼ 3.0, C4), 135.9 (d, J ¼ 10.0,
C3), 165.7 (d, J ¼ 2.2, C]O); 1H NMR (CDCl3) d 1.33 (t, 6H, J ¼
7.1, POCH2CH3), 1.40 (t, 3H, J ¼ 7.1, COCH2CH3), 4.00–4.28 (m,
4H, POCH2), 4.35–4.46 (m, 2H, COCH2), 7.49–7.60 (m, 1H, ArH),
7.94–8.08 (m, 1H, ArH), 8.22 (d, 1H, J ¼ 7.8, C4–H), 8.46 (d, 1H, J
¼ 13.8, C2–H), [M + H]+ ¼ 287.1048, C13H20O5P requires
287.1048.
261.1040, C15H18O2P requires 261.1039.
Butyl diphenylphosphinate (3d). White crystals; mp.: 95–96 ꢀC,
mp.:45 90–92 C; P NMR (CDCl3) d 31.2, dP (CDCl3)46 31.2; 13C
31
ꢀ
NMR (CDCl3) d 13.7 (CH3), 18.9 (CH2CH3), 32.7 (d, J ¼ 6.6,
OCH2CH2), 64.8 (d, J ¼ 6.1, OCH), 128.5 (d, J ¼ 13.1, C2)*, 131.7
(d, J ¼ 10.1, C3)*, 131.8 (d, J ¼ 2.8, C4), 132.1 (d, J ¼ 137.0, C1), *
1
may be reversed; H NMR (CDCl3) d 0.92 (t, 3H, J ¼ 7.3, CH3),
1.35–1.55 (d, 2H, CH2CH3), 1.62–1.80 (m, 2H, OCH2CH2), 4.03 (t,
2H, J ¼ 6.6, OCH2), 7.35–7.61 (m, 6H, ArH), 7.71–7.94 (m, 4H,
ArH); [M + H]+ ¼ 275.1196, C16H20O2P requires 275.1195.
Isobutyl diphenylphosphinate (3e). White crystals; mp.: 82–
83 ꢀC, mp.:44 79–80 ꢀC; 31P NMR (CDCl3) d 31.0; 13C NMR
(CDCl3) d 19.0 (CH3), 29.4 (d, J ¼ 6.9, CH), 70.9 (d, J ¼ 6.3,
OCH2), 128.6 (d, J ¼ 13.1, C2)*, 131.8 (d, J ¼ 10.1, C3)*, 131.9 (d, J
Diethyl 3-acetylphenylphosphonate (1n). 31P NMR (CDCl3) d
18.1, dP (CDCl3)39 18.1; 13C NMR (CDCl3) d 16.4 (d, J ¼ 6.4,
CH2CH3), 26.0 (C(O)CH3), 62.4 (d, J ¼ 5.6, OCH2), 129.0 (d, J ¼
14.8, C6), 129.5 (d, J ¼ 189.4, C1), 131.7 (d, J ¼ 10.6, C5), 131.9 (d,
J ¼ 3.0, C4), 136.0 (d, J ¼ 10.0, C3), 137.2 (d, J ¼ 13.9, C2), 197.2
(d, J ¼ 1.4, C]O); 1H NMR (CDCl3) d 1.35 (t, 6H, J ¼ 7.0,
CH2CH3), 2.65 (3H, C(O)CH3), 4.07–4.28 (m, 4H, OCH2), 7.55–
7.66 (m, 1H, ArH), 7.94–8.03 (m, 1H, ArH), 8.15 (d, 1H, J ¼ 7.5,
C4–H), 8.38 (d, 1H, J ¼ 13.8, C2–H); [M + H]+ ¼ 257.0943,
1
¼ 2.8, C4), 132.2 (d, J ¼ 137.2, C1), * may be reversed; H NMR
(CDCl3) d 0.96 (d, 6H, J ¼ 6.7, CH3), 1.89–2.07 (m, 1H, CH), 3.78
(t, 2H, J ¼ 6.3, OCH2), 7.34–7.56 (m, 6H, ArH), 7.65–7.88 (m, 4H,
ArH); [M + H]+ ¼ 275.1197, C16H20O2P requires 275.1195.
Isopentyl diphenylphosphinate (3f). White crystals; mp.: 55–
56 ꢀC, mp.:47 55–57 ꢀC; 31P NMR (CDCl3) d 31.2, dP (CDCl3)47
30.1; 13C NMR (CDCl3) d 22.3 (CH3), 24.6 (CH), 39.2 (d, J ¼ 6.6,
OCH2CH2), 63.4 (d, J ¼ 6.1, OCH2), 128.4 (d, J ¼ 13.1, C2)*, 131.5
(d, J ¼ 10.1, C3)*, 131.6 (d, J ¼ 137.0, C1), 132.0 (d, J ¼ 2.8, C4), *
C
12H18O4P requires 257.0943.
2.2. General procedure for the reaction of bromobenzene and
alkyl phenyl-H-phosphinates (2a–f). To the bromobenzene (0.11
mL, 1.0 mmol) was added alkyl phenyl-H-phosphinate [1.0
mmol: 0.15 mL of ethyl phenylphosphinate (2a), 0.17 mL of
propyl phenylphosphinate (2b), 0.17 mL of isopropyl phenyl-
phosphinate (2c), 0.18 mL of butyl phenylphosphinate (2d), 0.19
mL of isobutyl phenylphosphinate (2e), 0.21 g isopentyl phe-
nylphosphinate (2f)], triethylamine (0.16 mL, 1.1 mmol) and
Pd(OAc)2 (0.011 g, 0.05 mmol) and the resulting mixture was
irradiated by microwave as above (2.1) at 150 ꢀC for 5 min. The
mixture was puried as above using hexane–ethyl acetate 1 : 1
as the eluent. The products (3a–f) were obtained as white
crystals.
1
may be reversed; H NMR (CDCl3) d 0.88 (d, 6H, J ¼ 6.5, CH3),
1.60 (q, 2H, J ¼ 6.7, OCH2CH2), 1.68–1.85 (m, 1H, CH), 4.04 (q,
2H, J ¼ 6.5, OCH2), 7.34–7.56 (m, 6H, ArH), 7.65–7.85 (m, 4H,
ArH); [M + H]+ ¼ 289.1353, C17H22O2P requires 289.1352.
2.3. General procedure for the reaction of secondary phosphine
oxides with bromoarenes. The tertiary phosphine oxides (4a–d
and 6a–c) were prepared from the corresponding bromoarene
(2.0 mmol: 0.21 mL of bromobenzene, 0.34 g of 4-bromoto-
luene, 0.38 g 4-bromo-chlorobenzene and 0.22 mL 4-bromo-
uorobenzene) and the secondary phosphine oxide [2.0 mmol:
0.40 g of diphenylphosphine oxide, 0.27 g of dipropylphosphine
oxide (5a), 0.32 g of dibutylphosphine oxide (5b) and 0.46 g of
dibenzylphosphine oxide (5c)] [in the case of dialkylphosphine
oxides in acetonitrile (1 mL)], as above (2.1). The only difference
is that, in the case of dialkylphosphine oxides (5a–c), the solvent
Ethyl diphenylphosphinate (3a). White crystals; mp.: 43–44 ꢀC,
31
mp.:42 39–41 C, P NMR (CDCl3) d 32.2, dP (CDCl3)43 31.5; 13C
ꢀ
NMR (CDCl3) d 16.5 (d, J ¼ 6.6, CH3), 61.1 (d, J ¼ 5.9, OCH2),
128.4 (d, J ¼ 13.1, C2)*, 131.6 (d, J ¼ 10.1, C3)*, 131.7 (d, J ¼
1
137.0, C1), 132.0 (d, J ¼ 2.8, C4), * may be reversed; H NMR
22814 | RSC Adv., 2014, 4, 22808–22816
This journal is © The Royal Society of Chemistry 2014